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Abstract: Ibogaine, administered as a single oral dose (1-25 mg/kg body weight), has been used as an addiction-interrupting 
agent. Its effects persist for up to 72 h. Ex vivo results showed that ibogaine induced cellular energy consumption and res-
titution, followed by increased reactive oxygen species production and antioxidant activity. Therefore, the aim of this work 
was to explore the effect of a single oral dose of ibogaine (1 or 20 mg/kg body weight) on antioxidative defenses in rat liver 
and erythrocytes. Six and 24 h after ibogaine administration, histological examination showed glycogenolytic activity in 
hepatocytes, which was highest after 24 h in animals that received 20 mg/kg ibogaine. There were no changes in the activi-
ties of superoxide dismutases, catalase, glutathione peroxidase, glutathione reductase and glutathione-S-transferase in the 
liver and erythrocytes after ibogaine treatment, regardless of the dose. Hepatic xanthine oxidase activity was elevated in rats 
that received 20 mg/kg compared to the controls (p<0.01), suggesting faster adenosine turnover. TBARS concentration was 
elevated in the group treated with 1 mg/kg after 24 h compared to the controls (p<0.01), suggesting mild oxidative stress. 
Our results show that ibogaine treatment influenced hepatic redox homeostasis, but not sufficiently to remodel antioxidant 
enzyme activities at 6 and 24 h post-ibogaine application.
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INTRODUCTION
Ibogaine is the main alkaloid in the root bark of the 
plant Tabernanthe iboga [1], which has been used by the 
natives of western-central Africa to overcome fatigue, 
hunger and thirst, and at higher doses, to provoke 
dreamlike hallucinations for spiritual rituals [2]. In 
the “ibogaine medical subculture”, predominantly in 
Europe and America, it is used to facilitate abstinence 
from a variety of addictive substances (such as cocaine, 
heroin, methadone and alcohol), when ibogaine is 
most frequently administered as a single oral dose 
in the range from 1-25 mg/kg of body weight (b.w.) 
[2-4]. In the most recent publication [5] in the Clini-
cal Guidelines for Ibogaine-Assisted Detoxification, 
published by the Global Ibogaine Therapy Alliance 
(GITA), it is suggested that dosing should never exceed 
24 mg/kg in a 24 h interval. It is also suggested that a 
single initial booster dose (threshold dose, usually 1 
to 5 mg/kg) is administered before the single larger 
treatment dose which should not be administered 2 or 
3 h after the initial dose, but at least within the 24-36 h 
time frame after application of the initial booster dose. 
Alper et al. [6] reported that a subset of 33 individuals 
was treated for the indication of opioid withdrawal 
with a single dose of ibogaine averaging 19.3 mg/
kg. The U.S. Food and Drug Administration (FDA) 
Advisory Panel formally approved human trials with 
1, 2, and 5 mg/kg of ibogaine, and clinical trial (also 
approved by the FDA) in 1995 recommended similar 
doses [7]. Based on existing animal data, Schep et al. 
[8] suggested that appropriate safety factors should 
be applied, including a maximum oral dosage limit 
of less than 1 mg/kg. Therefore, for our experiment 
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we chose to explore the effects of a single oral dose of 
either 1 or 20 mg/kg b.w.
Ibogaine’s anti-addictive activity is achieved 
through its effects on receptors (N-methyl-D-aspartate 
[9], nicotinic [10], 5-hydroxytryptamine 2A (5-HT2A), 
muscarinic [1] and kappa, sigma-2 and mu opioid 
receptors [1]), inhibition of monoamine oxidase [1], 
antagonism of 5-HT and dopaminergic transporters 
[1], and through adaptive changes in ATP-related 
cell energy homeostasis [11-13]. Paškulin et al. [14] 
showed an increase in the production of energy-related 
enzymes in rat brain after intraperitoneal (i.p.) injection 
of 20 mg/kg b.w., and in yeast Saccharomyces cerevisiae 
[11] cultivated with ibogaine at a concentration of 1 
mg/L, which corresponds to the dose in the brain. It 
was also shown that ibogaine caused rapid depletion 
of ATP that was accompanied by increased production 
of reactive oxygen species (ROS) [13] and activation 
of antioxidant defense enzymes in yeast [11]. While 
ibogaine in vitro did not show any significant anti-
oxidant properties per se [12], the observed ibogaine-
associated increase in activities of antioxidant enzymes 
(cytosolic copper-zinc superoxide dismutase (SOD1), 
glutathione reductase (GR) [13] and catalase (CAT) 
[15]) in different in vitro [12] and ex vivo [13] model 
systems supported ibogaine as a pro/antioxidative 
agent. In previous work on yeast [11], elevated expres-
sion of metabolic enzymes involved in glycolysis and 
of SOD protein were detected after 5 h at a dose of 1 
mg/L ibogaine (equivalent to ibogaine levels found 
in brains of rats that received 20 mg/kg b.w., i.p.). 
However, among the proteins identified by matrix-
assisted laser desorption/ionization-time of flight mass 
spectrometry (MALDI-TOF MS) that were induced 
after 24 and 72 h in brains of rats (that received 20 mg/
kg b.w., i.p.), SOD was not listed [14], suggesting spe-
cies- and tissue-specific effects of ibogaine. Therefore, 
in our experiments we measured the activities of the 
antioxidant enzymes, SOD1, mitochondrial manga-
nese superoxide dismutase (SOD2), CAT, glutathione 
peroxidase (GSH-Px) and GR after ibogaine in vivo, 
per os (p.o.) application (1 or 20 mg/kg b.w.) after 6 
and 24 h. Ibogaine has a blood half-life in humans 
ranging between 4-8 h, and the elimination half-life 
of ibogaine in humans is from 4-7 h [7,16-18]. Thus, 
the time point of 6 h in our experiments was the mean 
time of its half-life used to examine the expression of 
antioxidant enzymes in yeast (5 h).
In mammals, ibogaine is converted to its active 
metabolite, noribogaine (12-hydroxyibogamine). 
Studies in human subjects after single oral ibogaine 
administration showed its complex pharmacokinetic 
profiles. Ibogaine is cleared rapidly from the blood, 
and replaced by noribogaine [18]. However, ibogaine 
metabolism in the rat is different when compared to 
the human. Ibogaine is eliminated faster than noribo-
gaine [1] and 24 h after p.o. administration about 65% 
of the ibogaine in rats [19], and even 90% in humans 
[7], can be eliminated via the urine and feces. Ac-
cording to Bauman et al., 24 h after intravenous (i.v.) 
administration of ibogaine, noribogaine still persists 
in rat blood, unlike ibogaine, which can no longer 
be detected [20]. Therefore, in the present work, we 
also measured the concentration of both ibogaine and 
noribogaine in blood plasma.
Having in mind ibogaine pharmacokinetics, as 
well as its influence on both energy metabolism and 
the activity of antioxidant enzymes explored ex vivo 
[11,12,15] and in vitro [13] using different doses and 
experimental models, herein we examined the effects 
of ibogaine in vivo after application of a single dose (1 
or 20 mg/kg b.w., p.o.) on rat liver and erythrocytes 
after 6 and 24 h. Histological examination of the liver 
was performed in order to (i) visualize the potential 
changes in the amount of glycogen (as representation 
of energy metabolism), and (ii) to examine the possible 
morphological effects on hepatocytes. In the light of 
the documented effect of ibogaine on cellular energet-
ics, we measured blood glucose concentration. Food 
and water consumption and the specific gravity of the 
urine were also monitored. The metabolic function of 
the liver was estimated by measuring the activity of 
xanthine oxidase (XOD; purine turn-over) and glu-
tathione S-transferases (GST), as well as the level of 
bilirubin and urobilinogen in the urine. Furthermore, 
thiobarbituric acid reactive substances (TBARS) were 
measured as markers of possible oxidative damage 
to the liver and total and non-protein free sulfhydryl 
(-SH) groups in the liver as the marker of thiol-based 
redox state. The general systemic oxidative effect of 
ibogaine was assessed by monitoring the changes in 
activities of antioxidative enzymes in the liver and 
erythrocytes.
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MATERIALS AND METHODS
Animals
All procedures complied with the EEC Directive on the 
protection of animals used for experimental and other 
scientific purposes and were approved by the Ethical 
Committee for the Use of Laboratory Animals of the 
Institute for Biological Research “Siniša Stanković”, 
University of Belgrade, No. 02-03/16. Male Wistar rats, 
3-months of age, b.w. 290-320 g, were housed individu-
ally under standard laboratory conditions day/night 
12 h/12 h, at 22°C with free access to food and water.
Design of the experiment
Ibogaine hydrochloride (PubChem CID: 197059, pu-
rity 98.93%) was a kind gift from the Sacrament of 
Transition, Maribor, Slovenia; ibogain hydrochloride 
(Remøgen, Phytostan Enterprises Inc., Canada, pu-
rity 99.9%) was provided by Mara Bresjanac from the 
LNPR project funded by the ARRS Program P3-0171. 
Ibogaine was dissolved in dH2O by strong vortexing 
(at a stock concentration of 2 mg/mL) and maintained 
in the dark until use. The animals were divided into 
six groups (6 animals per group) and treated with one 
dose of ibogaine p.o. by gavage (1 or 20 mg/kg b.w.). 
The control groups were gavaged with an equal amount 
of dH2O. All animals received 1 mL of liquid (dH2O 
or ibogaine solution of appropriate concentration) per 
100 g b.w. by gavage. The experimental groups were as 
follows: C6 – control treated with dH2O, decapitated 
after 6 h; C24 – control treated with dH2O, decapitated 
after 24 h; L6 – low dose ibogaine (1 mg/kg b.w.), de-
capitated after 6 h; L24 – low dose ibogaine (1 mg/kg 
b.w.), decapitated after 24 h; H6 – high dose ibogaine 
(20 mg/kg b.w.), decapitated after 6 h; H24 – high 
dose ibogaine (20 mg/kg b.w.), decapitated after 24 h.
Blood preparation
When the rats were killed, blood was collected in trans-
parent heparinized tubes (500 I.U. per mL of blood). 
Blood plasma was separated from erythrocytes by 
centrifugation (MiniSpin, Eppendorf, at 3000 x g, for 
10 min) and stored at -20oC until analysis. Erythro-
cytes were washed three times with saline (0.9% w/w) 
and stored at -20oC until use. Antioxidant enzymes 
and XOD were measured in erythrocyte hemolysates 
(hemolyzed by ice cold dH2O).
Determination ibogaine and noribogaine 
concentrations in blood plasma
A validated liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) method [21] was used for the 
determination of ibogaine and noribogaine in blood 
plasma samples. Sample pretreatment consisted of 
simple protein precipitation with a double volume of 
acetonitrile. Plasma calibration standards were pre-
pared by adding the appropriate amounts of working 
standard solutions and prazepam (internal standard) 
to drug free plasma. All samples and standards were 
treated adequately to prevent decomposition of ibo-
gaine and noribogaine due to light exposure. The com-
pounds (ibogaine, noribogaine and prazepam) were 
separated with gradient elution on Zorbax XDB-CN 
(75 mm x 4.6 mm i.d., 3.5 µm). The LC-MS/MS instru-
ment consisted of the Agilent 1100 HPLC system and 
the tandem quadrupole mass spectrometer, Quattro 
micro™ API, from Waters, with an electrospray oper-
ating in positive ionization mode. The software used 
was MassLynx 4.1. Two SRM transitions were acquired 
for ibogaine (311→174, 122), noribogaine (297→160, 
122) and for the internal standard (325→105, 271). The 
calibration curves for both compounds in the plasma 
were linear in a prepared range from 0.1 to 100.0 ng/
mL, with a correlation coefficient of at least 0.996. The 
limit of quantification was 0.2 ng/mL.
Liver preparation
After decapitation, the liver was perfused with cold 
saline (0.9% w/w) and excised. A portion of the left 
lobe of the perfused liver was fixed in 4% parafor-
maldehyde solution in phosphate buffered saline pH 
7.4 for 24 h. The remaining liver tissue was frozen in 
liquid nitrogen and stored at -70°C.
Preparation of micrographs
After 24 h of tissue fixation, the liver samples were dehy-
drated by increasing the concentrations of ethanol and 
xylol, and then embedded in Histowax (Histolaboduct 
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AB, Göteborg, Sweden). Thin sections (5 μm) were 
cut on a rotary microtome (Leica, Germany), caught 
on glass slides and prepared for hematoxylin eosin 
(H&E) and Periodic Acid-Schiff (PAS) staining [22]. 
Hematoxylin dyes the nucleus blue, while the eosin dyes 
the cytoplasmic proteins, collagen and erythrocytes a 
reddish color. Glycogen granules in the cytoplasm are 
colored purple-magenta by the PAS staining method. 
Microscopic liver slides were examined using a Leica DM 
LS2 light microscope, and original photomicrographs 
were captured using a Canon PowerShot S70.
Qualitative analysis of the liver
The qualitative H&E analysis included histomorphologi-
cal liver examination of the hepatic lobules, dilatation 
of the central vein, dilatation of portal vein branches, 
hepatocyte edema, the presence of necrosis, portal in-
filtration of lymphocytes and plasma cells, hyperplasia 
of Kupffer cells and other pathological changes.
To compare the presence of glycogen in hepatocytes 
of animals from all experimental groups (quantitative 
analysis), the exact number of glycogen-positive cells 
was counted using a high-power field (HPF) at 400x 
magnifications of the areas (5 per each sample) around 
the central vein with the strongest glycogen signal. The 
presence of glycogen was expressed as the number of 
cells that contain glycogen per 100 cells.
Since the amount of glycogen in glycogen-positive 
cells can vary, in order to additionally clarify the ob-
tained results, we classified each sample into one of 
three classes according to the average intensity of PAS 
staining (i.e. the amount of glycogen) in all cells in 
the examined fields of individual sample as follows: + 
(weak staining) – the amount of glycogen <33.3% of 
the maximum; ++ (medium staining) – the amount 
of glycogen 33.3-66.7% of the maximum; +++ (strong 
staining) – the amount of glycogen >66.7% of the 
maximum (semiquantitative analysis). The scale is in 
the range between 0%, which represents cells negative 
to PAS staining, and 100%, which represents cells 
with the maximal observed intensity of PAS staining 
in hepatocytes of all groups (cells full with glycogen), 
with boundaries placed on one third and two thirds of 
the scale. To ensure objectivity, all PAS staining slides 
were interpreted by three different coauthors, with the 
mean of their findings as the final result.
Determination of concentration of TBARS  
and -SH groups
For measuring the level of TBARS and total and non-
protein free -SH groups, the perfused liver tissue was 
homogenized (3x10 s) and sonicated (3x15 s, at 10 kHz) 
in 0.05 M tris(hydroxymethyl)aminomethane (Tris), 1 
mM ethylenediaminetetraacetic acid (EDTA) buffer, 
pH 7.4. The sonicates were centrifuged (MiniSpin, 
Eppendorf) for 15 min at 9000 x g. The level of lipid 
peroxidation in liver was estimated according to the 
concentration of TBARS measured in liver sonicates 
according to the method of Rehncrona et al. [23]. The 
supernatants were mixed with equal volumes of 0.6% 
2-thiobarbituric acid and the mixtures were heated for 
10 min at 95°C. The absorbance of the supernatant 
was measured at 532 nm spectrophotometrically on a 
Shimadzu UV-160 (Shimadzu Scientific Instruments, 
Shimadzu Corporation, Kyoto, Japan). The amount 
of TBARS was calculated using malondialdehyde as 
a standard.
The concentrations of total -SH groups were measured 
according to Ellman’s protocol customized for a mi-
crotiter plate [24]. Supernatants were mixed directly on 
a microtiter plate with 0.1 M potassium phosphate buf-
fer (pH 7.3) and 3 mM 5,5’-dithiobis-(2-nitrobenzoic 
acid (Ellman’s reagent). Measurements were performed 
10 min after development of the yellow color. Absor-
bance was measured at 412 nm (Multiskan Spectrum, 
Thermo Fisher Scientific Oy, Vantaa, Finland). For 
determination of non-protein free -SH groups, sul-
fosalicylic acid was added before centrifugation and 
measurements were performed in the supernatant.
Determination of the activities of antioxidant 
enzymes, XOD and GST
For determination of antioxidative enzyme, XOD and 
GST activities, liver samples were homogenized and 
sonicated as described above in 0.25 M sucrose Tris-
EDTA buffer pH 7.4, and centrifuged at 105000 x g at 
4°C for 90 min. The enzyme activities were measured 
in supernatants spectrophotometrically using a Shi-
madzu UV-160 spectrometer. The activities of SOD1 
and SOD2 were determined by the adrenaline method 
[25]. One SOD unit (U) is defined as the amount of 
enzyme required to decrease the rate of adrenaline 
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autooxidation by 50%. CAT activity was measured by 
monitoring H2O2 consumption at 230 nm, according 
to Beutler [26]. Glutathione peroxidase (GSH-Px) 
activity was measured using t-butyl hydroperoxide as 
a substrate, by a modification of the assay described 
by Paglia and Valentine [27]. After the reaction of the 
substrate with glutathione (GSH) by sample GSH-Px, 
the remaining oxidized glutathione (GSSG) in the 
reaction mixture is reduced by GR that consumes 
NADPH. The method is based on the follow-up of the 
absorbance at 340 nm (absorbance peak of NADPH). 
The activity of GR was determined using the method 
based on NADPH oxidation and GSSG reduction [28]. 
The activity of GST was determined using 1-chloro-2,4-
dinitrobenzene and GSH as substrates and monitoring 
the increase in absorbance at 340 nm [29]. XOD activity 
was determined by monitoring uric acid production 
in the presence of xanthine as a substrate, according 
to Terada et al. [30].
Measurement of hemoglobin concentration
Hemoglobin concentration in erythrocytes was mea-
sured by the method of Drabkin [31].
Protein determination
The concentrations of proteins in liver samples were 
measured by the method of Lowry using bovine serum 
albumin as a standard [32].
Determination of the amounts of consumed food 
and water
At the end of the experiment, the amount of consumed 
food and water for each animal was measured and 
expressed as g (for food) or mL (for water) per h per 
kg b.w. The total volume of water consumed during 
the experiment was calculated as a sum of the volume 
that the animals have drank freely and the volume 
applied by gavage.
Determination of blood glucose concentration
Glucose concentration was measured in the whole blood 
immediately after decapitation using a Blood Glucose 
Test Strip TOUCH-IN® Micro, ApexBio (Taiwan).
Determination of urine parameters
Bilirubin, urobilinogen and urine specific gravity were 
determined using commercial strips, Uriscan urine test 
strips, YD Diagnostics (Yongin, Republic of Korea).
Data analysis and statistical procedures
Statistical analyses were performed according to the 
protocols described by Hinkle et al. [33]. The presence 
of glycogen in hepatocytes, the activities of antioxidant 
enzymes, XOD, GST, the concentrations of glucose, 
TBARS, the concentrations of total and non-protein 
free -SH groups and the amount of consumed food and 
water were compared by two-way ANOVA (ibogaine 
dose and time after treatment as factors), followed by 
Tukey’s HSD post hoc test. The statistical significance 
of the distribution of the intensity of PAS staining was 
calculated by the Kolmogorov-Smirnov χ2-test. The 
significance level was p<0.05, with values expressed 
as the mean±standard error of the mean (SEM).
RESULTS
Concentration of ibogaine and noribogaine in 
blood plasma
Six hours after administration of 1 mg/kg b.w., the 
plasma of only two animals out of six contained ibo-
gaine measurable above the detection limit (0.9±0.2 ng/
mL), while noribogaine was measured in all six plasma 
samples of L6 animals (6.0±2.2 ng/mL). The samples 
from the L24 group were under the limit of detection 
of either ibogaine or noribogaine in blood plasma at 
24 h post-administration. In the H6 group, ibogaine 
was measured in five out of six animals (2.2±1.5 ng/
mL), and noribogaine was measured in all six animals 
(70.5±7.2 ng/mL). In the H24 group, ibogaine was 
above the limit of detection in the blood plasma of 
two out of six animals (0.9±0.2 ng/mL), along with 
noribogaine, which was detected in all six animals 
(5.7±3.2 ng/mL).
138 Arch Biol Sci. 2019;71(1):133-144
Presence of glycogen and color intensity of PAS 
staining in the liver
Histological analysis of the left lobe of livers by H&E 
staining (Fig. 1) revealed a normal liver morphology 
without any histopathological changes in all animals. 
Both control and treated H&E-stained livers presented 
the hexagonal structure of the classic lobule, without 
signs of necrosis, portal infiltration of lymphocytes 
and plasma cells, or of hyperplasia of Kupffer cells. 
PAS staining (Fig. 2) revealed a different proportion 
of glycogen-positive cells, as well as intensity of PAS 
staining (i.e. the amount of glycogen) of cells in the 
experimental groups. Analysis for the presence of gly-
cogen in hepatocytes (Fig. 3) showed that the number 
of glycogen-positive cells per 100 cells was decreased 
in groups treated with 1 and 20 mg/kg b.w. of ibogaine 
(two-way ANOVA, effect of dose, p<0.001). Treatment 
with 1 mg/kg b.w. of ibogaine caused a decrease in 
Fig. 1. Micrographs of rat liver after H&E-staining. Histomor-
phological examination showed regular, hexagonal, lobular liver 
structure without histopathological changes. Group C (control 
groups): animals treated with dH2O, decapitated after 6 h (C6) – A, 
and after 24 h (C24) – B. Group L: animals treated with ibogaine 1 
mg/kg b.w., decapitated after 6 h (L6) – C, and after 24 h (L24) – D; 
group H: animals treated with ibogaine 20 mg/kg b.w., decapitated 
after 6 h (H6) – E, and after 24 h (H24) – F. A-F: H&E staining, 
magnification: 200x. cv – central vein, pt – portal triads.
Fig. 2. Micrographs of rat liver after PAS-staining. Differences 
in the numbers of glycogen-positive cells and staining intensity 
of glycogen are shown in representative fields. Group C (control 
groups): animals treated with dH2O, decapitated after 6 h (C6) – A 
and after 24 h (C24) – B; group L: animals treated with ibogaine 
1 mg/kg b.w., decapitated after 6 h (L6) – C, and after 24 h (L24) 
– D; group H: animals treated with ibogaine 20 mg/kg b.w., de-
capitated after 6 h (H6) – E, and after 24 h (H24) – F. A-F: PAS 
staining, magnification: 400x. cv – central vein. Example of a cell 
that contains glycogen are in circle.
Fig. 3. Presence of glycogen in hepatocytes (quantitative analy-
sis). The presence of glycogen was expressed as the number of 
cells that contain glycogen per 100 total cells; body weight (b.w.). 
Results are expressed as the mean±SEM. Statistical significance 
was calculated by two-way ANOVA (dose (D) and time (T) as 
factors; F and p values are presented) and post hoc Tukey’s HSD 
test. *** – p<0.001, ** – p<0.01, * – p<0.05.
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the proportion of glycogen-positive cells after 6 h, 
which remained at the same level after 24 h. On the 
other hand, treatment with 20 mg/kg b.w. of ibogaine 
also caused a decrease after 6 h, followed by an even 
greater decrease after 24 h (two-way ANOVA, effect 
of time, p<0.05; interaction of dose and time, p<0.05; 
Tukey’s HSD test, H6 vs. H24, p<0.01). Analysis of in-
tensity of the PAS-staining, i.e. the amount of glycogen 
(semiquantitative analysis) (Fig. 4) showed significant 
differences among the groups (Kolmogorov-Smirnov 
chi-squared test, p<0.001). In both control groups, 
all samples were classified as +++. Treatment with 1 
mg/kg b.w. of ibogaine caused a decrease in staining 
intensity of glycogen after 6 h (three specimens were 
classified as + and three as ++), whereas after 24 h, 
the staining intensity of glycogen was slightly greater 
(two samples were classified as + and four as ++). 
However, treatment with 20 mg/kg b.w. of ibogaine 
also caused a mild decrease after 6 h (five specimens 
were classified as ++ and one as +++), followed by a 
greater decrease after 24 h (five specimens were clas-
sified as + and one as ++).
Fig. 4. Intensity of PAS staining, i.e. amount of glycogen (semi-
quantitative analysis). Each sample is classified in one of the three 
classes: + amount of glycogen <33.3% of the maximum; ++ amount 
of glycogen 33.3-66.7% of the maximum; +++ amount of glyco-
gen >66.7% of the maximum. Group C (control groups): animals 
treated with dH2O, decapitated after 6 h (C6) – A, and after 24 h 
(C24) – B; group L: animals treated with ibogaine 1 mg/kg b.w., 
decapitated after 6 h (L6) – C, and after 24 h (L24) – D; group H: 
animals treated with ibogaine 20 mg/kg b.w., decapitated after 6 h 
(H6) – E, and after 24 h (H24) – F; body weight (b.w.). Statistical 
significance was calculated by the Kolmogorov-Smirnov chi-
squared test; χ2 and p values are presented.
Fig. 5. Concentration of TBARS (A) and activity of xanthine oxi-
dase (XOD) in liver (B); body weight (b.w.), nonsignificant (ns). 
Results are expressed as the mean±SEM. Statistical significance 
was calculated by two-way ANOVA (dose (D) and time (T) as 
factors; F values are presented, p<0.05) and post hoc compared 
by Tukey’s HSD test; * represents Tukey’s HSD test significant 
difference p<0.05.
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Concentration of TBARS and -SH groups and 
enzyme activities
While there were no observable changes in the con-
centrations of total and non-protein free -SH groups 
(Table 1) in the liver, the concentration of TBARS was 
elevated in the L24 group (Fig. 5A). Two-way ANOVA 
revealed that XOD was higher in the livers of rats 
that received 20 mg/kg b.w. compared to the control, 
but the post hoc Tukey’s HSD test did not show any 
statistical significance among individual groups (Fig. 
5B). There were no differences in the activities of an-
tioxidant enzymes and GST in rat liver after ibogaine 
treatment, regardless of the dose used (Table 1). The 
same was found in erythrocytes, where the activity of 
antioxidant enzymes was similar in treated animals 
compared to controls (Table 2). In erythrocytes, there 
was no difference in XOD activity among groups.
Amounts of consumed food and water, blood 
glucose concentration and urine parameters
There were no significant differences in the consump-
tion of water and food. No difference in blood glucose 
concentration was observed after treatment with ibo-
gaine, regardless of dose and time of observation (Table 
3). There were no discernible changes in the bilirubin 
and urobilinogen levels or urine specific gravity in any 
of the treated groups when compared to the controls 
(data not shown).
Table 1. Activities of antioxidant enzymes (SOD1, SOD2, CAT, GSH-Px, GR), GST, XOD, concentration of TBARS, total and non-protein 
free -SH groups in the liver.
group time [h]
TBARS 
[nmol/g 
liver]
total free
–SH groups 
[μmol 
–SH/L]
non-protein 
free –SH 
groups 
[nmol–SH/L]
SOD1
[U/mg 
protein]
SOD2
[U/mg 
protein]
CAT
[μmol H2O2/
min/
mg protein]
GSH-Px 
[nmol 
NADPH/ 
min/mg 
protein]
GR
[nmol 
NADPH/
min/mg 
protein]
GST
[nmol GSH/
min/ mg 
protein]
XOD
[nmol uric 
acid/min/
mg protein]
C
6 7.35±0.77 0.83±0.06 0.10±0.03 23.97±0.86 2.89±0.16 130.38±1.66 135.66±6.78 89.04±1.52 637.05±64.69 0.076±0.009
24 7.01±0.97 0.80±0.03 0.12±0.03 20.89±3.36 2.87±0.43 122.93±11.59 126.72±10.43 85.43±6.9 727.73±62.66 0.069±0.011
L
6 9.62±1.31 0.80±0.03 0.13±0.01 22.67±2.19 3.09±0.24 122.93±10.81 153.78±9.15 95.20±4.83 716.25±47.76 0.079±0.006
24 10.04±0.86* 0.84±0.05 0.13±0.02 23.39±2.73 2.24±0.25 169.32±1.84 136.40±8.75 81.95±4.77 629.80±29.21 0.107±0.009
H
6 7.95±1.22 0.84±0.03 0.12±0.03 21.12±2.78 2.32±0.10 160.48±26.41 148.62±7.68 91.48±3.61 744.73±26.41 0.114±0.007
24 9.34±0.59 0.81±0.04 0.12±0.01 22.84±1.81 2.49±0.19 137.28±9.95 142.43±13.95 85.22±6.10 679.32±71.00 0.105±0.016
two-way ANOVA
dose:
F=5.37;
p<0.05
ns ns ns ns ns ns ns ns
dose:
F=7.02;
p<0.01
The control group (C) was treated with dH2O; groups treated with ibogaine were as follows: 1 mg/kg b.w. (L), 20 mg/kg b.w. (H). 
Values are expressed as the mean±SEM. Results were compared by two-way ANOVA, dose and time as factors, p<0.05 and post hoc compared by Tukey’s HSD test;  
* represents Tukey’s HSD test significant difference compared to C24, p<0.05. 
Nonsignificant – ns.
Table 2. Activities of antioxidant enzymes (SOD1, CAT, GSH-Px, GR), and XOD in erythrocytes. There were no significant changes 
between groups.
group time [h] SOD1[U/g Hb]
CAT 
[mmol H2O2/ min/g Hb]
GSH-Px 
[μmol NADPH/ min/g Hb]
GR 
[µmol NADPH/ min/g Hb]
XOD 
[nmol uric acid/min/g Hb]
C
6 20.06±2.27 539.11±88.06 73.84±7.28 37.62±8.99 3.79±0.69
24 25.17±3.46 541.91±100.4 97.30±12.24 57.88±20.10 3.71±0.73
L
6 26.95±1.21 525.60±23.94 79.93±5.29 45.19±3.08 4.37±0.56
24 26.36±3.61 488.72±51.66 72.77±10.94 41.30±6.74 4.15±0.71
H
6 26.57±1.38 403.04±16.18 74.84±3.46 32.13±9.54 4.47±0.78
24 23.77±4.56 442.46±54.31 57.81±8.41 20.16±6.30 4.10±0.97
two-way ANOVA ns ns ns ns ns
The control group (C) was treated with dH2O; groups were treated with ibogaine were as follows: 1 mg/kg b.w. (L), 20 mg/kg b.w. (H). 
Values are expressed as the mean±SEM. Results were compared by two-way ANOVA, dose and time as factors, p<0.05 and post hoc compared by Tukey’s HSD test. 
Hemoglobin – Hb; nonsignificant - ns.
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DISCUSSION
In spite of the existing knowledge about the molecu-
lar mechanisms of ibogaine action and its effects on 
ROS and redox homeostasis, there is little published 
research about its various systemic in vivo oxidant/
antioxidant effects. It has been shown that ibogaine 
can act as a pro/antioxidant, promoting increased 
antioxidant activity in a dose- and time-dependent 
manner in different model systems, including yeast 
[11] and human erythrocytes [13]. However, our re-
sults presented here show that liver and erythrocyte 
antioxidant enzyme activities after administration of 
ibogaine p.o. at doses of 1 and 20 mg/kg b.w. at 6 and 
24 h post-application did not significantly differ from 
those in control rats. However, TBARS was elevated 
after application of 1 mg/kg b.w., suggesting a mild 
prooxidant and systemic effect that was insufficient 
to promote an increase in activities of antioxidant en-
zymes to a measurable level. Our results also showed 
that ibogaine caused a depletion of glycogen in the 
liver, suggesting extensive utilization of glucose. In 
animals that received the low dose, ibogaine caused a 
depletion that was partially compensated at 24 h. On 
the other hand, in the liver of animals that received 
20 mg/kg ibogaine, the depletion in liver glycogen 
was more profound at 6 h post-ibogaine administra-
tion, and even greater after 24 h. It would appear that 
ibogaine increased overall tissue energy consumption, 
which was both time- and dose-dependent, confirming 
earlier results that showed ibogaine-mediated deple-
tion of cellular energy stores were followed by ATP 
re-synthesis and elevated ROS production, as well as 
restitution of energy homeostasis [11]. The degrees of 
change in these processes in vivo can be tissue-specific; 
however, if we take into account that there were no 
changes in blood glucose concentration, we can assume 
that ibogaine-associated tissue energy depletion was 
compensated from blood glucose that was maintained 
at a steady state via liver glycogen utilization. It has 
been reported that ibogaine itself can induce elevation 
of local cerebral glucose consumption [34], but at a 
higher dose and after a different route of application 
(40 mg/kg, i.p.). Thus, it would appear that the effect 
of ibogaine on glucose metabolism is tissue-, dose- and 
route-of-application-dependent.
No histopathological changes were observed in 
the liver after administration of either dose of ibo-
gaine; however, we detected glycogen depletion. Urine 
analysis showed that the metabolic function of the liver 
was preserved. However, the higher dose of ibogaine 
induced a slight elevation in XOD that suggests a faster 
turnover of ATP and adenosine. The xanthine oxidase 
reaction can cause tissue injury in hypoxic organs due 
to increased superoxide, as well as enhanced adenine 
nucleotide breakdown that occurs during oxygen depri-
vation. Faster turnover implies an elevated synthesis of 
uric acid that possesses significant antioxidant proper-
ties so that ibogaine application can be considered as 
pro/antioxidative. Uric acid itself is a strong antioxidant 
and its elevation was found as a side effect of XOD 
prooxidant action during ischemia-reperfusion and 
hypoxia when intensive ATP depletion occurs [35-
37]. Since no change in XOD activity was observed 
in the blood, it seems that the faster purine turnover 
was not systemic but only characteristic for the liver.
Measurements of ibogaine and noribogaine concen-
trations in blood plasma revealed a pharmacokinetics 
that was generally consistent with earlier publications. 
In our experiment with animals treated p.o. (dose 1 mg/
kg b.w.), noribogaine was detected after 6 h, while the 
concentration of ibogaine was low, close to the thresh-
old of detectability by the employed method. After 24 
h, neither ibogaine nor noribogaine were detected in 
the plasma of rats treated with the low-dose, suggest-
ing efficient metabolism of ibogaine and/or possible 
sequestration into adipose tissue and the brain. It was 
Table 3. Amount of consumed food and water, and blood glucose 
concentration. There were no significant changes between groups.
group time[h]
food
[g/h/kg b.w.]
water
[mL/h/kg b.w.]
glucose
[mmol/L]
C
6 2.98±0.26 4.15±0.59 6.53±0.40
24 2.68±0.38 4.60±0.48 6.47±0.41
L
6 3.15±0.20 4.77±0.36 6.05±0.31
24 3.07±0.21 4.56±0.29 5.75±0.27
H
6 3.13±0.16 4.91±0.41 5.75±0.27
24 3.01±0.13 4.50±0.37 6.14±0.54
two-way ANOVA ns ns ns
The control group (C) was treated with dH2O; groups were treated with 
ibogaine were as follows: 1 mg/kg b.w. (L), 20 mg/kg b.w. (H). 
Values are expressed as the mean±SEM. Results were compared by two-
way ANOVA, dose and time as factors, p<0.05 and post hoc compared 
by Tukey’s HSD test. 
Nonsignificant – ns.
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shown that ibogaine largely accumulates in adipose tis-
sue and to some extent in the brain [38]. Ibogaine and 
noribogaine were detected in blood plasma after 6 h in 
the group treated with 20 mg/kg b.w. At 24 h following 
the 20 mg/kg b.w. of ibogaine, the plasma noribogaine 
concentration was 20 times higher than that of ibo-
gaine. This is in accordance with the known ibogaine 
metabolism and pharmacokinetics [39]. Ibogaine is 
subject to a substantial “first pass” effect [38] and there 
is a significant difference in ibogaine metabolism even 
among humans [40,41]. The maximal concentration 
of ibogaine in blood or plasma and the time needed 
for ibogaine to reach its maximal concentration in the 
plasma are dependent on animal sex, dose and type of 
application (i.v., subcutaneous (s.c.), i.p. or p.o.) [20]. 
After i.v. application of 10 mg/kg to rats, the maximal 
concentration in whole blood (18.2 μg/mL) was at-
tained already after 1 min [20], while after i.p. applica-
tion of 40 mg/kg to rats, ibogaine reached the maximal 
concentration in whole blood (3.9 μg/mL) after 6 min 
[20]. In our experiment where ibogaine application 
was p.o., its incorporation was slower. Furthermore, 
after i.v. application ibogaine bypasses the first pass of 
liver-mediated detoxification. Hough et al. [38] revealed 
that in female rats, ibogaine (40 mg/kg) administered 
s.c. achieved a higher concentration in blood plasma 
after 1 h and 12 h when compared to its i.p. route of 
administration. After p.o. application of 5 mg/kg, the 
maximal concentration of ibogaine in the plasma was 10 
ng/g (about 10 ng/mL) [19], but the time when ibogaine 
peaked was not reported. Having in mind that ibogaine 
peaks in blood plasma within 1-2 h after p.o. application 
in humans [18], the ibogaine concentration measured 
in our experiment after 6 and 24 h for both doses seems 
reasonable for this route of application. Moreover, it is 
clear that the maximal concentration attained in the 
blood or plasma after p.o. application is much lower 
compared to other types of application. Based on the 
pharmacokinetics described by Jeffcoat [19] and other 
authors [7,18,20,38,39], it is not possible to extrapolate 
precisely the blood plasma ibogaine and noribogaine 
concentrations from different graphs due to variations 
in animal models and treatments. Furthermore, Shrep 
et al. [8] suggested additional safety factors need to be 
applied to animal data prior to considering an appropri-
ate and safe initial dose for humans.
Ibogaine is metabolized in the liver by the cyto-
chrome P-450-dependent system and different classes 
of GST that eliminate a broad spectrum of xenobiotics 
and final metabolic products [42]. Liver GSTs are in-
ducible enzymes that follow liver xenobiotic metabo-
lism. However, our results showed no changes in GST 
activity, suggesting that ibogaine could be metabolized 
before the time points when GST activity was mea-
sured or when the treatment with ibogaine did not 
significantly affect the liver microsomal system. This 
assumption is supported by the fact that there were 
no changes in the concentration of GSH, as concluded 
based on the measurement of non-protein free -SH 
groups, which is a cofactor utilized during GST activity.
In our experiment, ibogaine did not affect food 
and water consumption. This is in agreement with 
the results of Rezvani et al. [43], who showed that 
ibogaine treatment (i.p., p.o.) with doses of 10, 30, 
and 60 mg/kg had no significant effect on food and 
water consumption.
In spite of the changes in liver glycogen, there were 
no changes in the activities of the studied antioxidant 
enzymes in either the liver or erythrocytes. At the 
doses used in our study, it seems that ibogaine did not 
provoke a significant antioxidative response either in 
the liver or at the systemic level. However, since ibo-
gaine effects are rapid, it is possible that compensatory 
antioxidative activities by antioxidative enzymes were 
carried out soon after ibogaine administration, much 
earlier than at 6 or 24 h. Previous results from in vitro 
studies on yeast [11,12], ex vivo data obtained in human 
erythrocytes [13] and isolated rat uterus [15] showed 
that antioxidant enzymes responded to an ibogaine 
challenge by changing their activities. Furthermore, 
previous results on yeast showed that 5 h is the time 
period necessary for ROS production to return to the 
normal cellular level after application of ibogaine at 
doses ranging from 1 to 20 mg/L [11]. Additionally, 
the liver has a greater antioxidant capacity compared 
to other tissues [44,45], and it seems that the applied 
doses were not sufficient to create a persistent anti-
oxidant response at the level of antioxidant enzyme 
activities after 6 or 24 h.
Our results also suggest that ibogaine at the applied 
doses did not disturb liver redox equilibrium since the 
levels of -SH groups and GR activity were similar in 
treated and control groups at both ibogaine doses and 
time points. However, there was a slight elevation of 
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TBARS in the treated group after 24 h, implying that 
cell membranes were oxidatively attacked and dam-
aged, yielding lipid peroxide byproducts. Ibogaine is 
a lipophilic molecule. There are membrane lipid rafts 
that store ATP [46]. In our earlier work [13], we showed 
that ibogaine addition to fresh whole blood (10 and 
20 μM) releases ATP from erythrocytes within 1 h of 
incubation. The release of ATP from erythrocytes is 
accompanied by increases in SOD1 and GR activi-
ties. However, our results showed that there were no 
changes in erythrocyte SOD1 and GR after 6 h or 24 h 
after the application of either dose. The much higher 
concentrations of ibogaine  (3.1 μg/mL and 6.2 μg/
mL) applied in our earlier work on erythrocytes ex 
vivo [13], which were several times higher than the 
concentrations of ibogaine and noribogaine measured 
in blood plasma herein, could be the reason for the 
apparent absence of antioxidant effects of ibogaine 
on erythrocytes.
CONCLUSION
Our results confirm ibogaine-associated changes in 
tissue energy and its dose- and time-dependent redox-
related actions. No overt pathological signs of damage 
to hepatic cells and tissue were detected. However, due 
to the different rates of rat and human metabolism, a 
linear extrapolation of results (and applied doses) from 
rat to human should be avoided. Since our research 
is based on doses used by humans, additional safety 
factors need to be applied to the animal data before 
recommending a safe initial dose for humans.
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